Evidence map›Paper›PMID 25625931›Full record

ReviewHuman vaccines & immunotherapeutics2014

The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.

Michelle Paff, Daniela Alexandru-Abrams, Frank P K Hsu, Daniela A Bota

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. PTGES/PGEOncogene · 2020
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Prospect of rindopepimut in the treatment of glioblastoma.Expert opinion on biological therapy · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michelle Paffa Department of Neurological Surgery ; University of California, Irvine ; Orange , CA USA.
Daniela Alexandru-Abrams
Frank P K Hsu
Daniela A Bota
University of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma Multiforme (GBM) is the most common type of brain tumor and it is uniformly fatal. The community standard of treatment for this disease is gross or subtotal resection of the tumor, followed by radiation and temozolomide. At recurrence bevacizumab can be added for increased progression free survival. Many challenges are encountered while trying to devise new drugs to treat GBM, such as the presence of the blood brain barrier which is impermeable to most drugs. Therefore in the past few years attention was turned to immunological means for the treatment of this devastating disease. EGFRvIII targeting has proven a good way to attack glioblastoma cells by using the immune system. Although in still in development, this approach holds the promise as a great first step toward immune-tailored drugs for the treatment of brain cancers.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBlood-Brain BarrierBrain NeoplasmsCamptothecinCancer VaccinesChemoradiotherapyDacarbazineDisease-Free SurvivalErbB ReceptorsGlioblastomaHumansImmunotherapyIrinotecanAntibodies, Monoclonal, HumanizedBevacizumabCamptothecinCancer VaccinesDacarbazineEGFR protein, humanepidermal growth factor receptor VIIIErbB ReceptorsIrinotecanrindopepimutTemozolomideVaccines, SubunitAb, antibodyACTIVATE, A Complementary Trial of an Immunotherapy Vaccine against Tumor Specific EGRFvIIIAPC, antigen-presenting cellBBB, blood brain barrierbrainCD25, cluster of differentiation 25CD4, cluster of differentiation 4CNS, central nervous systemCPT-11, irinotecan, CamptosarCTL, Cytotoxic T lymphocytesD, dayDTH, delayed-type hypersensitivityEGFRVIIIEGFRvIII, The epidermal growth factor receptor variant IIIEORTC, European Organization for Research and Treatment of CancerGAGE, G antigen gene familyGBM, Glioblastoma MultiformeglioblastomaGM-CSF, Granulocyte-macrophage colony-stimulating factorGrb2, Growth factor receptor-bound protein 2HLA, human leukocyte antigenIL-10, Interleukin-10IL-12, Interleukin-12IL-2, Interleukin-2INF-g, Interferon gammaKLH, keyhole limpet hemocyaninKPS, Karnofsky performance statusLPS, lipopolysaccharideMGMT, O-6-methylguanine-DNA methyltransferaseMHC, major histocompatibility complexNCIC, National Cancer Institute of CanadaOS, overall survivalPFS, progression-free survivalPGE2, prostaglandin E2Ras, rat sarcoma genesSEER, Surveillance, Epidemiology, and End Results ProgramTGF-b, transforming growth factor betaTH2 cells, T helper type 2 cellstherapiesTMZ, temozolomideTreg cells, regulatory T cellsTTP, time to progressionvaccineVEGF, Vascular endothelial growth factorWHO, World Health OrganizationY, year

Identifiers

PMID25625931
PMCPMC4514075
OpenAlexW2086978682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.